Literature DB >> 35277375

Optimizing the future: how mathematical models inform treatment schedules for cancer.

Deepti Mathur1, Ethan Barnett2, Howard I Scher2, Joao B Xavier3.   

Abstract

For decades, mathematical models have influenced how we schedule chemotherapeutics. More recently, mathematical models have leveraged lessons from ecology, evolution, and game theory to advance predictions of optimal treatment schedules, often in a personalized medicine manner. We discuss both established and emerging therapeutic strategies that deviate from canonical standard-of-care regimens, and how mathematical models have contributed to the design of such schedules. We first examine scheduling options for single therapies and review the advantages and disadvantages of various treatment plans. We then consider the challenge of scheduling multiple therapies, and review the mathematical and clinical support for various conflicting treatment schedules. Finally, we propose how a consilience of mathematical and clinical knowledge can best determine the optimal treatment schedules for patients.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical trials; mathematical models; treatment schedules

Mesh:

Year:  2022        PMID: 35277375      PMCID: PMC9117454          DOI: 10.1016/j.trecan.2022.02.005

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  68 in total

1.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Authors:  M Hidalgo; L L Siu; J Nemunaitis; J Rizzo; L A Hammond; C Takimoto; S G Eckhardt; A Tolcher; C D Britten; L Denis; K Ferrante; D D Von Hoff; S Silberman; E K Rowinsky
Journal:  J Clin Oncol       Date:  2001-07-01       Impact factor: 44.544

Review 2.  Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All.

Authors:  Nicolas André; Daniel Orbach; Eddy Pasquier
Journal:  Trends Cancer       Date:  2020-06-26

3.  Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.

Authors:  Aki Morikawa; Elisa de Stanchina; Elena Pentsova; Margaret M Kemeny; Bob T Li; Kendrick Tang; Sujata Patil; Martin Fleisher; Catherine Van Poznak; Larry Norton; Andrew D Seidman
Journal:  Clin Cancer Res       Date:  2019-04-15       Impact factor: 12.531

4.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Authors:  Martin R Stockler; Vernon J Harvey; Prudence A Francis; Michael J Byrne; Stephen P Ackland; Bernie Fitzharris; Guy Van Hazel; Nicholas R C Wilcken; Peter S Grimison; Anna K Nowak; M Corona Gainford; Akiko Fong; Lisa Paksec; Tatiana Sourjina; Diana Zannino; Val Gebski; R John Simes; John F Forbes; Alan S Coates
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

5.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

Authors:  G Bonadonna; M Zambetti; P Valagussa
Journal:  JAMA       Date:  1995-02-15       Impact factor: 56.272

6.  Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Marco Colleoni; Weixiu Luo; Per Karlsson; Jacquie Chirgwin; Stefan Aebi; Guy Jerusalem; Patrick Neven; Erika Hitre; Marie-Pascale Graas; Edda Simoncini; Claus Kamby; Alastair Thompson; Sibylle Loibl; Joaquín Gavilá; Katsumasa Kuroi; Christian Marth; Bettina Müller; Seamus O'Reilly; Vincenzo Di Lauro; Andrea Gombos; Thomas Ruhstaller; Harold Burstein; Karin Ribi; Jürg Bernhard; Giuseppe Viale; Rudolf Maibach; Manuela Rabaglio-Poretti; Richard D Gelber; Alan S Coates; Angelo Di Leo; Meredith M Regan; Aron Goldhirsch
Journal:  Lancet Oncol       Date:  2017-11-17       Impact factor: 41.316

7.  Evolutionary dynamics of cancer in response to targeted combination therapy.

Authors:  Ivana Bozic; Johannes G Reiter; Benjamin Allen; Tibor Antal; Krishnendu Chatterjee; Preya Shah; Yo Sup Moon; Amin Yaqubie; Nicole Kelly; Dung T Le; Evan J Lipson; Paul B Chapman; Luis A Diaz; Bert Vogelstein; Martin A Nowak
Journal:  Elife       Date:  2013-06-25       Impact factor: 8.140

Review 8.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2016-09-27

9.  A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.

Authors:  Xavier Elharrar; Dominique Barbolosi; Joseph Ciccolini; Christophe Meille; Christian Faivre; Bruno Lacarelle; Nicolas André; Fabrice Barlesi
Journal:  BMC Cancer       Date:  2016-04-20       Impact factor: 4.430

10.  Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.

Authors:  Renee Brady-Nicholls; Jingsong Zhang; Tian Zhang; Andrew Z Wang; Robert Butler; Robert A Gatenby; Heiko Enderling
Journal:  Neoplasia       Date:  2021-07-20       Impact factor: 5.715

View more
  1 in total

1.  Risk Prediction of Ureaplasma urealyticum Affecting Sperm Quality Based on Mathematical Model and Cross-Sectional Study.

Authors:  Huang Liu; Kai Yang; Liping He; Shenghui Zhu; Tao Pang; Zhiyong Zhu; Yunyi Yao; Houbin Zheng; Qingqi Zeng; Xinzong Zhang
Journal:  Comput Math Methods Med       Date:  2022-05-25       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.